Review
Version 1
Preserved in Portico This version is not peer-reviewed
Potential Clinical Benefits of TDM of Antimicrobials in Japan
Version 1
: Received: 18 January 2022 / Approved: 19 January 2022 / Online: 19 January 2022 (14:29:36 CET)
How to cite: Ebihara, F.; Hamada, Y.; Maruyama, T.; Kimura, T. Potential Clinical Benefits of TDM of Antimicrobials in Japan. Preprints 2022, 2022010277. https://doi.org/10.20944/preprints202201.0277.v1 Ebihara, F.; Hamada, Y.; Maruyama, T.; Kimura, T. Potential Clinical Benefits of TDM of Antimicrobials in Japan. Preprints 2022, 2022010277. https://doi.org/10.20944/preprints202201.0277.v1
Abstract
Under the Japanese health insurance system, medicines undergoing therapeutic drug monitoring (TDM) can be billed for medical fees if they meet the specified requirements. In Japan, TDM of vancomycin, teicoplanin, aminoglycosides, and voriconazole, which are used for the treatment of infectious diseases, is common practice. This means the levels of antimicrobial agents are measured in-house using chromatography. This review describes personalized medicine based on the use of chromatography as a result of the current situation in Japan.
Keywords
HPLC; TDM; ceftriaxone; daptomycin; linezolid
Subject
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment